东亚药业(605177)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

605177 东亚药业

已收盘 05-21 15:00:00

{"stockData":{"symbol":"605177","market":"SH","secType":"STK","nameCN":"东亚药业","latestPrice":25.9,"timestamp":1716274800000,"preClose":26.28,"halted":0,"volume":930871,"delay":0,"floatShares":113999999,"shares":113999999,"eps":1.0746,"marketStatus":"已收盘","marketStatusCode":5,"change":-0.38,"latestTime":"05-21 15:00:00","open":26.28,"high":26.45,"low":25.71,"amount":24145200,"amplitude":0.0282,"askPrice":25.9,"askSize":64,"bidPrice":25.89,"bidSize":3,"shortable":0,"etf":0,"ttmEps":1.0746,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1716341400000},"adr":0,"adjPreClose":26.28,"symbolType":"stock","openAndCloseTimeList":[[1716255000000,1716262200000],[1716267600000,1716274800000]],"highLimit":28.91,"lowLimit":23.65,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":113600920,"pbRate":1.55,"roa":"--","roe":"1.19%","epsLYR":1.07,"committee":-0.230769,"marketValue":2942000000,"floatMarketCap":2942000000,"peRate":24.101992,"changeRate":-0.0145,"turnoverRate":0.0082,"status":1},"requestUrl":"/m/hq/s/605177/tweets","defaultTab":"tweets","newsList":[{"id":"2437497981","title":"东亚药业：头孢唑肟钠新车间满销满产，年产3,685吨医药及中间体、4,320吨副产盐项目预计2025年建成投产","url":"https://stock-news.laohu8.com/highlight/detail?id=2437497981","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2437497981?lang=zh_cn&edition=full","pubTime":"2024-05-21 17:55","pubTimestamp":1716285358,"startTime":"0","endTime":"0","summary":"5月21日消息， 东亚药业 披露投资者关系活动记录表显示，目前头孢唑肟钠新车间处于满销满产的状态。年产3,685吨医药及中间体、4,320吨副产盐项目（一期）预计将于25年建成投产。关于原材料价格，自去年9月份起部分原材料价格开始逐步回落，截至目前大部分原料价格已基本触底。未来的员工持股计划或股权激励请以公司公告为准。值得关注的是，2024年公司会有新增折旧情况，主要是2023年12月份有两个IPO项目结项所致。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024052118001487827b00&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024052118001487827b00&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2436124170","title":"东亚药业(605177.SH)拟合作设立医药投资基金并成立医药开发公司 拓展下游制剂业务","url":"https://stock-news.laohu8.com/highlight/detail?id=2436124170","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2436124170?lang=zh_cn&edition=full","pubTime":"2024-05-20 16:30","pubTimestamp":1716193801,"startTime":"0","endTime":"0","summary":"据悉，合伙企业总认缴出资额为1亿元，公司作为有限合伙人拟以自有资金出资1900万元认缴合伙企业等值份额，占合伙企业股权比例的19%。公告显示，公司本次拟合作设立医药投资基金并共同发起设立医药开发公司，能够充分利用原料药技术与产能优势，协助公司实现下游制剂业务的拓展，最终实现向原料药+制剂一体化发展转型。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1123211.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2436997041","title":"东亚药业：合作设立医药投资基金并共同发起设立医药开发公司的进展，现已完成工商登记并取得营业执照","url":"https://stock-news.laohu8.com/highlight/detail?id=2436997041","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2436997041?lang=zh_cn&edition=full","pubTime":"2024-05-17 18:47","pubTimestamp":1715942826,"startTime":"0","endTime":"0","summary":"5月17日消息， 东亚药业 公告，公司于2024年5月16日与杭州嘉富天成股权投资管理有限公司、台州市海盛产业投资有限公司、临海市金融投资有限公司、台州市开投资本运营有限公司共同出资设立台州嘉富泽立股权投资合伙企业 ，现已完成工商登记手续，并取得了由临海市市场监督管理局颁发的《营业执照》。同时，公司与合伙企业已签订《合作协议》，合伙企业将与其他投资方共同发起设立一家专业从事 仿制药 开发的药证公司。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024051718502887742988&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024051718502887742988&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2436399572","title":"东亚药业最新公告：拟合作设立医药投资基金 并共同发起设立医药开发公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2436399572","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2436399572?lang=zh_cn&edition=full","pubTime":"2024-05-17 17:09","pubTimestamp":1715936983,"startTime":"0","endTime":"0","summary":"东亚药业公告，拟使用自有资金与杭州嘉富天成股权投资管理有限公司、台州市海盛产业投资有限公司、临海市金融投资有限公司(“临海金投”)、台州市开投资本运营有限公司共同出资设立台州嘉富泽立股权投资合伙企业(有限合伙)；后续与该合伙企业共同投资设立一家专业从事制剂开发的杭州善融医药研究有限公司(暂定名，最终名称以工商核准登记为准)。以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405171713238b11fb3b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405171713238b11fb3b&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2436961419","title":"东亚药业（605177）5月17日主力资金净卖出265.85万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2436961419","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2436961419?lang=zh_cn&edition=full","pubTime":"2024-05-17 15:17","pubTimestamp":1715930274,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年5月17日收盘，东亚药业报收于25.48元，下跌0.93%，换手率1.39%，成交量1.58万手，成交额3996.98万元。近5日资金流向一览见下表：该股主要指标及行业内排名如下：东亚药业2024年一季报显示，公司主营收入3.53亿元，同比下降4.63%；归母净利润2403.92万元，同比上升3.53%；扣非净利润2037.66万元，同比下降9.58%；负债率40.58%，投资收益189.83万元，财务费用-116.6万元，毛利率25.4%。东亚药业主营业务：化学原料药、医药中间体的研发、生产和销售。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024051700021863.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2435191591","title":"东亚药业(605177.SH)：依帕司他原料药获韩国原料药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2435191591","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2435191591?lang=zh_cn&edition=full","pubTime":"2024-05-14 19:13","pubTimestamp":1715685218,"startTime":"0","endTime":"0","summary":"智通财经APP讯，东亚药业(605177.SH)公告，公司收到韩国食品药品监督管理局(韩国MFDS)原料药品注册证书，产品名称为依帕司他。据悉，依帕司他属于糖尿病用药，可抑制糖尿病病人体内山梨醇含量的异常升高，有效预防、改善和治疗糖尿病并发的末梢神经障碍，如麻木感、疼痛感等。更多港股重磅资讯，下载智通财经app更多港股及海外理财资讯，请点击www.zhitongcaijing.com（搜索“智通财经”）；欲加入智通港股投资群，请加智通客服微信(ztcjkf)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1121238.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2435961865","title":"东亚药业：依帕司他原料药获得韩国原料药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2435961865","media":"21世纪经济报道","top":-1,"share":"https://www.laohu8.com/m/news/2435961865?lang=zh_cn&edition=full","pubTime":"2024-05-14 18:31","pubTimestamp":1715682660,"startTime":"0","endTime":"0","summary":"南方财经5月14日电，东亚药业公告，依帕司他原料药获得韩国原料药品注册证书。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240514183152876851ae&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240514183152876851ae&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2435174329","title":"东亚药业：债券持有人可转债持有比例变动达到10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2435174329","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2435174329?lang=zh_cn&edition=full","pubTime":"2024-05-13 19:44","pubTimestamp":1715600665,"startTime":"0","endTime":"0","summary":"浙江东亚药业股份有限公司公告，公司于2024年5月13日收到池正明先生、台州市瑞康投资合伙企业（有限合伙）通知，自2024年3月15日至2024年5月13日，池正明先生通过集中竞价的方式转让“东亚转债”751,120张，约占可转债发行总量的10.89%；台州市瑞康投资合伙企业（有限合伙）通过集中竞价的方式转让“东亚转债”151,820张，约占可转债发行总量的2.20%。本次转让合计约占可转债发行总量的13.09%。本次转让后，公司控股股东、实际控制人及实际控制人的一致行动人合计持有“东亚转债”258.308万张，约占可转债发行总量的37.44%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405131944288b01493c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405131944288b01493c&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2434389488","title":"东亚药业(605177)4月30日股东户数0.93万户，较上期减少4.29%","url":"https://stock-news.laohu8.com/highlight/detail?id=2434389488","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2434389488?lang=zh_cn&edition=full","pubTime":"2024-05-10 17:05","pubTimestamp":1715331928,"startTime":"0","endTime":"0","summary":"证券之星消息，近日东亚药业披露，截至2024年4月30日公司股东户数为9261.0户，较4月20日减少415.0户，减幅为4.29%。在化学制药行业个股中，东亚药业股东户数低于行业平均水平，截至4月30日，化学制药行业平均股东户数为3.3万户。从股价来看，2024年4月20日至2024年4月30日，东亚药业区间跌幅为0.34%，在此期间股东户数减少415.0户，减幅为4.29%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024051000031930.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2434187884","title":"东亚药业筹码连续3期集中","url":"https://stock-news.laohu8.com/highlight/detail?id=2434187884","media":"证券时报网","top":-1,"share":"https://www.laohu8.com/m/news/2434187884?lang=zh_cn&edition=full","pubTime":"2024-05-10 15:58","pubTimestamp":1715327880,"startTime":"0","endTime":"0","summary":"东亚药业5月10日在交易所互动平台中披露，截至4月30日公司股东户数为9261户，较上期减少415户，环比降幅为4.29%。这已是该公司股东户数连续第3期下降，累计降幅达18.99%，也就是说筹码呈持续集中趋势。证券时报数据宝统计，截至发稿，东亚药业收盘价为27.00元，下跌5.43%，筹码持续集中以来股价累计上涨30.50%。具体到各交易日，18次上涨，6次下跌。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405101558458af021e0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405101558458af021e0&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2434865608","title":"东亚药业（605177）5月10日主力资金净卖出501.33万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2434865608","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2434865608?lang=zh_cn&edition=full","pubTime":"2024-05-10 15:15","pubTimestamp":1715325332,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年5月10日收盘，东亚药业报收于27.0元，下跌5.43%，换手率2.8%，成交量3.18万手，成交额8743.14万元。近5日资金流向一览见下表：该股主要指标及行业内排名如下：东亚药业2024年一季报显示，公司主营收入3.53亿元，同比下降4.63%；归母净利润2403.92万元，同比上升3.53%；扣非净利润2037.66万元，同比下降9.58%；负债率40.58%，投资收益189.83万元，财务费用-116.6万元，毛利率25.4%。东亚药业主营业务：化学原料药、医药中间体的研发、生产和销售。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024051000022602.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2434272000","title":"东亚药业跌幅超5% 主力资金净流出","url":"https://stock-news.laohu8.com/highlight/detail?id=2434272000","media":"智选洞察","top":-1,"share":"https://www.laohu8.com/m/news/2434272000?lang=zh_cn&edition=full","pubTime":"2024-05-10 14:01","pubTimestamp":1715320897,"startTime":"0","endTime":"0","summary":"05月10日，东亚药业股价大幅下跌，截至14点01分，东亚药业下跌5.04%，报27.11元/股，成交7290万元，换手率2.33%，振幅5.01%。资金动向截止发稿，东亚药业获得主力净流出611万元，其中超大单流入101万元，大单流出712万元。主营业务及业绩东亚药业公司主营业务为化学原料药、医药中间体的研发、生产和销售。最新财报显示，今年一季报，东亚药业实现营业收入3.53亿元，同比减少4.63%，净利润为2,403.92万元，同比增长3.53%，基本每股收益为0.21元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405101405517a5928b1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202405101405517a5928b1&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2434611086","title":"AI制药新进展：谷歌推出新一代模型 产业链一览","url":"https://stock-news.laohu8.com/highlight/detail?id=2434611086","media":"腾讯自选股","top":-1,"share":"https://www.laohu8.com/m/news/2434611086?lang=zh_cn&edition=full","pubTime":"2024-05-09 08:14","pubTimestamp":1715213647,"startTime":"0","endTime":"0","summary":"美东时间周三，谷歌DeepMind发布了新一代预测蛋白质结构的AlphaFold 3模型，能够帮助科学家更精确地针对疾病机制，从而开发出更有效的治疗药物。据太平洋证券医药，AI制药内涵丰富，主要包括：数字生物学、计算机药物发现、实验室自动化、AI 辅助临床试验等。整体而言AI技术在制药领域的应用价值主要体现在缩短试验周期、节省成本、促进新事物发现、提升试验成功概率等。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240509075702861ebda0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20240509075702861ebda0&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2433748946","title":"东亚药业：5月7日接受机构调研，光大证券、开源证券等多家机构参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2433748946","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2433748946?lang=zh_cn&edition=full","pubTime":"2024-05-08 17:47","pubTimestamp":1715161666,"startTime":"0","endTime":"0","summary":"证券之星消息，2024年5月8日东亚药业发布公告称公司于2024年5月7日接受机构调研，光大证券、开源证券、申万宏源证券、华安证券、平安证券、财通证券、山西证券、中信建投证券、兴业证券参与。截至目前，已递交申报注册1项，另外已完成放大生产4项、工艺验证6项。目前天气逐渐转热，细菌类疾病可能高发，抗生素属于刚需药品，整体需求趋于平稳。东亚药业主营业务：化学原料药、医药中间体的研发、生产和销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024050817483987dff531&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024050817483987dff531&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2433424611","title":"东亚药业（605177）5月7日主力资金净卖出21.02万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2433424611","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2433424611?lang=zh_cn&edition=full","pubTime":"2024-05-07 15:14","pubTimestamp":1715066068,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年5月7日收盘，东亚药业报收于27.6元，上涨2.99%，换手率1.91%，成交量2.16万手，成交额5865.43万元。近5日资金流向一览见下表：该股主要指标及行业内排名如下：东亚药业2024年一季报显示，公司主营收入3.53亿元，同比下降4.63%；归母净利润2403.92万元，同比上升3.53%；扣非净利润2037.66万元，同比下降9.58%；负债率40.58%，投资收益189.83万元，财务费用-116.6万元，毛利率25.4%。东亚药业主营业务：化学原料药、医药中间体的研发、生产和销售。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024050700019483.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2433341243","title":"东亚药业(605177.SH)累计回购217.01万股 耗资5499.22万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2433341243","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2433341243?lang=zh_cn&edition=full","pubTime":"2024-05-06 15:45","pubTimestamp":1714981542,"startTime":"0","endTime":"0","summary":"智通财经APP讯，东亚药业(605177.SH)公告，截止2024年4月30日，公司通过集中竞价交易方式累计回购股份217.01万股，已回购股份占公司总股本的比例为1.91%，成交的最高价为32.68元/股，最低价为15.47元/股，已支付的总金额为5499.22万元(不含交易费用)。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1117478.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2431365247","title":"东亚药业04月30日获主力加仓367万元 环比增加1429.17%","url":"https://stock-news.laohu8.com/highlight/detail?id=2431365247","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2431365247?lang=zh_cn&edition=full","pubTime":"2024-04-30 15:17","pubTimestamp":1714461473,"startTime":"0","endTime":"0","summary":"04月30日, 东亚药业股价涨0.53%，报收26.51元，成交金额5815万元，换手率1.92%，振幅6.30%，量比1.42。东亚药业今日主力资金净流入367万元，上一交易日主力净流入24万元，今日环比增加1429.17%。该股近5个交易日上涨0.45%，主力资金累计净流入221万元；近20日主力资金累计净流入1.07亿元，其中净流入天数为15日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024043015250687c2a86f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024043015250687c2a86f&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2431401001","title":"东亚药业(605177.SH)发布一季度业绩 净利润2403.92万元 同比增长3.53%","url":"https://stock-news.laohu8.com/highlight/detail?id=2431401001","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2431401001?lang=zh_cn&edition=full","pubTime":"2024-04-29 15:46","pubTimestamp":1714376768,"startTime":"0","endTime":"0","summary":"智通财经APP讯，东亚药业(605177.SH)披露2024年第一季度报告，该公司报告期实现营业收入3.53亿元，同比下降4.63%。归属于上市公司股东的净利润2403.92万元，同比增长3.53%。归属于上市公司股东的扣除非经常性损益的净利润2037.66万元，同比下降9.58%。基本每股收益为0.21元/股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1114035.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2429102800","title":"东亚药业2023年业绩平稳增长，营收首次突破13亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2429102800","media":"览富财经网","top":-1,"share":"https://www.laohu8.com/m/news/2429102800?lang=zh_cn&edition=full","pubTime":"2024-04-24 14:20","pubTimestamp":1713939602,"startTime":"0","endTime":"0","summary":"2024年4月23日晚间，东亚药业披露2023年年度报告。在此基础上，得益于该公司“原料药+制剂”一体化战略加速落地，东亚药业经营规模持续扩大，2023年营业收入首次突破13亿大关。分产品来看，2023年，旗下β-内酰胺类抗菌药仍是营收主力，业务规模进一步扩张。2023年，东亚药业全年共计投入研发费用8173.76万元，同比大幅增长81.85％。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404241422438b4d90c3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404241422438b4d90c3&s=b","is_publish_highlight":false,"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2020-11-25","address":"浙江省台州市三门县浦坝港镇沿海工业城","stockEarnings":[{"period":"1week","weight":-0.03},{"period":"1month","weight":-0.0263},{"period":"3month","weight":0.388},{"period":"6month","weight":-0.1205},{"period":"1year","weight":0.0603},{"period":"ytd","weight":-0.0219}],"companyName":"浙江东亚药业股份有限公司","boardCode":"AI0027","perCapita":"12266股","boardName":"医药制造业","registeredCapital":"11360万元","compareEarnings":[{"period":"1week","weight":0.0039},{"period":"1month","weight":0.0302},{"period":"3month","weight":0.0702},{"period":"6month","weight":0.0314},{"period":"1year","weight":-0.0382},{"period":"ytd","weight":0.0615}],"survey":"　　浙江东亚药业股份有限公司的主营业务是从事化学原料药、医药中间体的研发、生产和销售；公司的主要产品是抗细菌药物、抗胆碱和合成解痉药、皮肤用抗真菌药、其他产品，产品主要涵盖抗细菌类药物（β-内酰胺类和喹诺酮类）、抗胆碱和合成解痉药物（马来酸曲美布汀）、皮肤用抗真菌药物等多个用药领域。公司累计获得授权专利36项，其中发明专利31项，是浙江省专利示范企业。公司多次承担省级重大科技专项、国家火炬计划项目、省重大国际科技专项、省重点高新技术产品开发项目等，多次获得浙江省和台州市科技进步奖等。","serverTime":1716321115085,"listedPrice":31.13,"stockholders":"9261人(较上一季度减少4.29%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"东亚药业(605177)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供东亚药业(605177)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"东亚药业,605177,东亚药业股票,东亚药业股票老虎,东亚药业股票老虎国际,东亚药业行情,东亚药业股票行情,东亚药业股价,东亚药业股市,东亚药业股票价格,东亚药业股票交易,东亚药业股票购买,东亚药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"东亚药业(605177)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供东亚药业(605177)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}